In 2025, KFF reported that 19% of employers with 200+ workers and 43% with 5,000+ workers covered GLP-1s for weight loss, and employers are expected to revisit coverage and cost-containment strategies each year as demand remains high
For some people, the idea of lifelong injections, the rising cost of medication, or the inconvenience of long-term maintenance just doesnt feel sustainable
However, a considerable proportion of affected individuals experience a protracted recovery [11, 12], highlighting the potential for significant and prolonged morbidity
We dont cut corners in our production
[DOI] [PMC free article] [PubMed] [Google Scholar] 29.Cummings J.L., Atri A., Feldman H.H., Hansson O., Sano M., Knop F.K., et al
Harpagoside-induced anaphylactic reaction in an IgE-independent manner both in vitro and in vivo